Comparative effectiveness casts first shadows across US industry.
Waltz
Emily
E
D035843:Biomedical Research / Q000191:economics / Q000331:legislation & jurisprudence; D001709:Biotechnology / Q000191:economics / Q000331:legislation & jurisprudence; D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D005380:Financing, Government; D006297:Health Services Accessibility; D009316:National Institutes of Health (U.S.) / Q000191:economics*; D012109:Research Support as Topic / Q000331:legislation & jurisprudence*; D016896:Treatment Outcome; D014481:United States; D037041:United States Government Agencies / Q000191:economics*